A list of commonly used measurement tools for psoriasis management and clinical trials.
The DermSat-7 is a patient-reported outcome measure designed to assess patient satisfaction with psoriasis treatment. It consists of seven key questions evaluating treatment effectiveness, convenience, and overall satisfaction, providing valuable insights for both patients and healthcare providers.
A simple 10-question validated questionnaire that has been used for more than 40 different skin conditions in over 80 countries and is available in over 110 languages to measure disease severity and quality of life.
A simple proxy for PASI and DLQI using body surface area (BSA) and one or more of Skin Pain Visual Analog Score (Skin Pain VAS), Itch numeric rating scale (Itch NRS), and patient global assessment (patGA).
Quantifies the severity of psoriasis measured by redness, thickness, and scaliness of the lesions, weighed by the area of involvement.
Physician’s assessment of the severity of disease based on a scale from clear to very severe.
Self-administered, patient-reported outcome measure (PRO) to assess symptom severity in chronic plaque psoriasis.
The Simplified Psoriasis Index (SPI) is a tool that has been developed to enable either healthcare professionals or patients with psoriasis to make regular assessments of disease severity and its impact on well-being. It also incorporates a summary of past behavior and treatment.
A 10-question questionnaire based on the experiences of children with skin disease. Available in both a text-only version and the Cartoon CDLQI, with each question illustrated by a cartoon based on the theme of the question, catering to younger children.
GET THE CDLQI
DOWNLOAD THE OFFICIAL APP (free) – Apple
DOWNLOAD THE OFFICIAL APP (free) – Google Play
A clinical tool used to assess the severity of nail psoriasis, focusing on specific features of nail involvement.
A clinical tool for evaluating the severity of psoriasis on the hands and feet. Based on erythema, scaling, and pustule presence, the PPPGA ranges from clear to severe.
A validated screening tool for psoriatic arthritis (PsA). It is recommended that patients with psoriasis who do not have a diagnosis of PsA complete an annual PEST questionnaire (NICE psoriasis guidelines 2012). A score of 3 or more indicates referral to rheumatology should be considered.
A clinical assessment tool used to measure the severity of psoriasis specifically on the scalp, based on erythema, scaling, and thickness.
A clinical outcome measure for the assessment of genital psoriasis severity that accounts for the erythematous clinical presentation of genital psoriasis.
A validated online measure designed to comprehensively evaluate disease activity in generalized pustular psoriasis, providing clinicians with a reliable tool to assess the severity and progression of the condition.
Includes validated tools that help clinicians accurately monitor disease severity, progression, and treatment response.
This confirms the reliability and accuracy in assessing disease severity and extent, providing essential tools for clinicians to effectively evaluate and manage generalized pustular psoriasis.
IPC does not endorse or accept any responsibility for the content of external websites.
IPC Jr. Councilor Towhida Noor reviews the psoriasis pipeline: selective TYK2 inhibitors, long-acting IL-17 and IL-23 biologics, and IL-36 blockade in GPP.
IPC Board Member and Treasurer Joel Gelfand, MD, MSCE, is the editor of a new textbook, Psoriasis: An Expert Global Perspective, now available for preorder from Elsevier. He worked with associate editors IPC President Bruce Strober, MD, PhD; IPC Vice President/President-Elect Claudia de la Cruz, MD; and IPC Chief Medical Officer Peter van de Kerkhof, MD, PhD. Nearly 50 authors from 20 countries contributed 30 chapters covering psoriasis from its earliest descriptions through genetics, immunology, and current therapies, with clinical images of psoriasis across diverse skin tones. All royalties support IPC.
PRE-ORDER YOUR COPY
In this video, IPC Councilor Rodrigo Garcia Salinas, MD, a rheumatologist from Argentina, explains how to recognize psoriatic arthritis early, including why joint pain, how long a patient has had psoriasis, and family history can matter more than skin severity alone. He also reviews how imaging helps catch early disease and how to choose treatment based on each patient’s joint, spine, and skin involvement.
IPC President Bruce Strober reviews the link between psoriasis and metabolic disease, drawing on findings from IPC’s recent paper in the Journal of the American Academy of Dermatology (JAAD). He translates this growing body of evidence into five concrete priorities from the 2025 IPC Think Tank for improving cardiometabolic screening and care.
